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415 Aortic arch repair for Stanford type A aortic dissection with distal
anastomosis to the proximal level of the distal aortic arch
Yoshio Mori, MD, PhD, Hajime Hirose, MD, PhD, Hisato Takagi, MD, PhD,
Yukio Umeda, MD, PhD, Yukiomi Fukumoto, MD, PhD, Katsuya Shimabukuro, MD, and
Yukihiro Matsuno, MD, Gifu, Japan
Since 1994, in type A dissection, we have performed our new transverse aortic arch
replacement in which the distal end of the graft is anastomosed between the left common
carotid artery and the left subclavian artery. At 5 years, the in-hospital death rate was 3.7%,
and the actuarial survival was 91%.
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420 Impact of sodium-hydrogen exchange inhibition by cariporide on death or
myocardial infarction in high-risk CABG surgery patients: Results of the
CABG surgery cohort of the GUARDIAN study
Steven W. Boyce, MD, Claus Bartels, MD, Roberto Bolli, MD, Bernard Chaitman, MD,
John C. Chen, MD, Eric Chi, PhD, Andreas Jessel, MD, Dean Kereiakes, MD,
John Knight, MD, Lars Thulin, MD, and Pierre Theroux, MD, on behalf of the GUARDIAN
Study Investigators, Washington, DC; Luebeck, Germany; Louisville, Ky; St. Louis, Mo;
Honolulu, Hawaii; Bridgewater, NJ; Cincinnati, Ohio; Bedford Park, Australia; Lund, Sweden;
and Montreal, Quebec, Canada
Cariporide, a novel sodium-hydrogen exchange inhibitor, may have cardioprotective effects
during myocardial ischemia/reperfusion. In the CABG cohort of the GUARD During Ischemia
Against Necrosis, cariporide, 120 mg tid, significantly reduced the primary composite endpoint
of incidence of death or MI at 36 days, although all-cause mortality for the most part remained
largely unaffected and was dependent on a dramatic reduction in MI.
428 Pharmacologic platelet anesthesia by glycoprotein IIb/IIIa complex
antagonist and argatroban during in vitro extracorporeal circulation
Shinji Kanemitsu, MD, Masakatsu Nishikawa, MD, Koji Onoda, MD, Takatsugu Shimono, MD,
Hideto Shimpo, MD, Akira Yazaki, MD, Kuniyoshi Tanaka, MD, Hiroshi Shiku, MD, and
Isao Yada, MD, Fukui, Japan
A peptide-mimetic glycoprotein IIb/IIIa complex antagonist, FK633, was effective to protect
against platelet loss and function during an in vitro heparinized extracorporeal circulation.
Combination of FK633 with the direct thrombin inhibitor argatroban further prevented platelet
loss and secretion, suggesting improved platelet protection with this pharmacologic strategy.
436 Insertion of a left ventricular assist device in patients without thorough
transplant evaluations: A worthwhile risk?
Mathew Williams, MD, Jennifer Casher, BA, Neel Joshi, BA, Todd Hankinson, BA,
Michelle Warren, BA, Mehmet Oz, MD, Yoshifumi Naka, MD, PhD, and Donna Mancini, MD,
New York, NY
Patients in acute cardiogenic shock may require placement of LVADs before undergoing
standard pretransplant evaluations. We found that survival of this patient population, before and
after transplant, is comparable with that of patients who undergo nonurgent LVAD placement
or medical therapy.
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